clinical trial · NCT03105336
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Kite, A Gilead Company·phase2·completed·n = 159
Follicular LymphomaMarginal Zone LymphomaIndolent Non-Hodgkin LymphomaAxicabtagene ciloleucelCyclophosphamideFludarabine
brief summary
The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.
started
Jun 6, 2017
primary completion
Dec 20, 2024
completion
Dec 20, 2024
last updated
Dec 23, 2025
detailed description
After completing at least 60 months (FL participants) or at least 24 months (MZL participants) of assessments in this study since the initial axicabtagene ciloleucel infusion and after agreement by the Sponsor, participants will transition to a long-term follow-up (LTFU) study, KT-US-982-5968 where they will complete the remainder of the 15 year follow-up assessments.
official title
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol